Neoadjuvant Immunotherapy with anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Grant Data
Project Title
Neoadjuvant Immunotherapy with anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Principal Investigator
Professor Cheung, Tan To
(Principal Investigator (PI))
Co-Investigator(s)
Professor Yau Chung Cheung Thomas
(Co-Investigator)
Professor Man Kwan
(Co-Investigator)
Professor Ng Irene Oi Lin
(Co-Investigator)
Duration
42
Start Date
2020-01-01
Completion Date
2023-06-30
Amount
1074927
Conference Title
Neoadjuvant Immunotherapy with anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Keywords
Anti-PD1, Borderline resectable, Checkpoint inhibitor, Hepatocellular carcinoma, Neoadjuvant
Discipline
Clinical TrialsGastroenterology/Hepatobiliary
Panel
Biology and Medicine (M)
HKU Project Code
17121219
Grant Type
General Research Fund (GRF)
Funding Year
2019
Status
Completed
Objectives
1 Primary objective: To describe pathological tumour response rate in patients treated with Nivolumab, the number of patients who demonstrate tumour necrosis and the percentages of necrosis will be documented. 2 Secondary objective: To describe short-term outcomes of surgery after administration of PD1 inhibitor, including operation time, blood loss, transfusion requirement, complication rate, recurrence-free survival, overall survival, safety and tolerability of nivolumab 3 Exploratory objective: To explore the potential biomarkers